Optimising Prevention of Secondary Stroke



[a] Vascular imaging is recommended in all patients and CTA or MRA from arch to vertex is appropriate for both anterior and posterior circulation stroke.

Kleindorfer DO et al. *Stroke*. 2021;52:e364-e467.
CTA: CT angiography; MRA: MR angiography; SOE: source of embolism; TEE: transesophageal echocardiography.

Factor XI Inhibitors for Secondary Prevention in Noncardioembolic Stroke: Phase 3 Trials

Trial	OCEANIC-Stroke[a]	LIBREXIA-STROKE[b]
Study design	Randomised, blind, placebo-controlled	Randomised, blind, placebo-controlled
NCT number	NCT05686070	NCT05702034
Study drug	Asundexian 50 mg QD + APT (duration: 3-31 mo)	Milvexian 25 mg BID + SAPT or DAPT
Primary outcome(s)	• Time to first occurrence of ischaemic stroke • Time to first occurrence of major bleeding (ISTH criteria)	• Time to first occurrence of ischaemic stroke up to global targeted endpoint date (~41 mo)
Countries, n	38	54
Sites, n	745	814
Estimated participants, n	12,300	15,000
Estimated study period	2023-2025	2023-2026

[a] **Participant countries:** Argentina, Australia, Austrian, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Kazakhstan, Korea (Republic of), Latvia, Lithuania, Malaysia, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States of America.

[b] **Participant countries:** Argentina, Australia, Austrian, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea (Republic of), Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States of America, Vietnam.

Clinicaltrial.gov: NCT05686070. Last update posted 3 March, 2025. Accessed 18 March, 2025.
Clinicaltrial.gov: NCT05702034. Last update posted: 3 March, 2025. Accessed 18 March, 2025.
(D/S)APT: (dual/single) antiplatelet therapy; ISTH: International Society on Thrombosis and Haemostasis.